These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10408499)

  • 1. Testing time as resistant HIV-1 faces next wave of attack.
    Mellors J
    Lancet; 1999 Jul; 354(9173):135. PubMed ID: 10408499
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-generation drugs fight resistant virus.
    STEP Perspect; 1999; 99(1):3. PubMed ID: 11367160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
    Erickson JW; Gulnik SV; Markowitz M
    AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effect of triterpenes from Crataegus pinatifida on HIV-I protease.
    Min BS; Jung HJ; Lee JS; Kim YH; Bok SH; Ma CM; Nakamura N; Hattori M; Bae K
    Planta Med; 1999 May; 65(4):374-5. PubMed ID: 10364847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The impact of resistance testing of HIV-1 to the HIV clinical setting in Japan].
    Yamamoto Y
    Nihon Rinsho; 2002 Apr; 60(4):769-74. PubMed ID: 11968786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
    Young B; Fransen S; Greenberg KS; Thomas A; Martens S; St Clair M; Petropoulos CJ; Ha B
    Antivir Ther; 2011; 16(2):253-6. PubMed ID: 21447875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
    Hicks C
    AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.
    Asahchop EL; Oliveira M; Brenner BG; Martinez-Cajas JL; Toni Td; Ntemgwa M; Moisi D; Dandache S; Stranix B; Tremblay CL; Wainberg MA
    Antiviral Res; 2010 Sep; 87(3):367-72. PubMed ID: 20541566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors.
    Pérez-Olmeda M; Del Romero J; Rubio A; Ruiz L; Rodríguez C; Leal M; Clotet B; Soriano V
    J Med Virol; 2001 Feb; 63(2):85-7. PubMed ID: 11170042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of resistance to antiretroviral drugs.
    Vella S
    AIDS Clin Care; 1997 Jun; 9(6):45-7, 49, 52. PubMed ID: 11364354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
    Buzon MJ; Erkizia I; Pou C; Minuesa G; Puertas MC; Esteve A; Castello A; Santos JR; Prado JG; Izquierdo-Useros N; Pattery T; Van Houtte M; Carrasco L; Clotet B; Ruiz L; Martinez-Picado J
    J Antimicrob Chemother; 2012 Jan; 67(1):32-8. PubMed ID: 21994909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 14. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.
    Descamps D; Apetrei C; Collin G; Damond F; Simon F; Brun-Vézinet F
    AIDS; 1998 Jun; 12(9):1109-11. PubMed ID: 9662212
    [No Abstract]   [Full Text] [Related]  

  • 15. [Basic approaches to anti-HIV resistance].
    Baba M
    Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
    Magiorkinis E; Paraskevis D; Detsika MG; Lu L; Magiorkinis G; Lazanas M; Imbrechts S; Van Laethem K; Vandamme AM; Pilot-Matias T; Molla A; Camacho RJ; Hatzakis A
    AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1223-9. PubMed ID: 21417947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV resistance testing: a new clinical tool.
    Jorden VS; Paul SM
    N J Med; 2000 Oct; 97(10):33-8. PubMed ID: 11064565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Your next nightmare: 28% of new HIV cases may be drug-resistant.
    AIDS Alert; 1999 Dec; 14(12):133-7. PubMed ID: 11366987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiclass primary antiretroviral drug resistance in a patient presenting HIV-1/2 dual infection.
    Castro E; Recordon-Pinson P; Cavassini M; Fleury H
    Antivir Ther; 2012; 17(3):593-4. PubMed ID: 22301389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.